Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Biofil Chemicals & Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was ₹75.7 Mil. Biofil Chemicals & Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₹275.9 Mil.
Hence, Biofil Chemicals & Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.27.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Biofil Chemicals & Pharmaceuticals Receivables Turnover Related Terms
Biofil Chemicals & Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BIOFILCHEM vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) has a Receivables Turnover of 0.27 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #931 out of 946 companies in the Drug Manufacturers industry, placing it in the top 98.4%.
Is Biofil Chemicals & Pharmaceuticals' Receivables Turnover too high?
Biofil Chemicals & Pharmaceuticals' current Receivables Turnover is 0.27. The Drug Manufacturers industry median Receivables Turnover is 5.10. Biofil Chemicals & Pharmaceuticals' value of 0.27 is 94.7% below this industry median. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #931 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #931 out of 946 companies for Receivables Turnover. This places Biofil Chemicals & Pharmaceuticals in the lower half of its industry. The industry median Receivables Turnover is 5.10. Biofil Chemicals & Pharmaceuticals' value of 0.27 is 94.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.10, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofil Chemicals & Pharmaceuticals's current Receivables Turnover of 0.27 is 94.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current Receivables Turnover is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.57, compared to a current price of ₹30.78 — trading 26% below its estimated fair value. The current Receivables Turnover is 0.27 and 94.7% below the Drug Manufacturers industry median of 5.10. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM), the current Receivables Turnover is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹30.78 is trading 26% below its estimated GF Value™ of ₹41.57.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:BIOFILCHEM:
Receivables Turnover: 0.27
GF Value™: ₹41.57 vs. price of ₹30.78 (26% below fair value)
Industry Position: 94.7% below the Drug Manufacturers median (#931 of 946)
No single metric tells the full story. See the NSE:BIOFILCHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
73GF Score
Get the complete analysis for NSE:BIOFILCHEM
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOFILCHEM has been successfully added to your 
